Seokwoo Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seokwoo Park has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Sejoong Kim
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
9 shared publications - Eun-Jeong Kwon
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
7 shared publications - Ho Jun Chin
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
5 shared publications - Jong Cheol Jeong
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
5 shared publications - Ki Young Na
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
5 shared publications - Giae Yun
Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea
3 shared publications
Latest Publications
- 17 June 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Genetic Landscape of Kidney Failure in a Korean Transplant Cohort
Background: Kidney failure represents the final, irreversible stage of chronic kidney disease (CKD), yet its genetic architecture remains incompletely defined compared to CKD. While prior studies largely focused on kidney function traits, the genetic determinants of kidney failure itself and its etiologic subtypes are poorly understood. Therefore, this study aimed to identify genetic loci associated with kidney failure and its subtypes and to evaluate the predictive performance of multiple polygenic risk scores (PRSs) for stratifying kidney failure risk. Methods: We performed a large-scale genome-wide association study (GWAS) using a dataset of 2,355 kidney failure patients across three subtypes defined by primary disease, along with 152,131 controls. PRSs for type 2 diabetes, hypertension, estimated glomerular filtration rate (eGFR), and CKD were calculated, and a multi-PRS model was derived. Results: The GWAS identified multiple kidney failure-associated loci, including HLA-DRB1 for all kidney failure and glomerulonephritis as the primary disease, and COL24A1 for hypertensive kidney failure at genome-wide significance (P-8 ), implicating distinct immune and hypertension-related pathways in kidney failure pathogenesis. PRS analysis revealed that genetically distinct components of type 2 diabetes, hypertension, CKD, and eGFR were significantly linked to kidney failure risk across subtypes (OR=1.1–2.5). A combined multi-PRS model demonstrated superior predictive performance (OR=1.5–2.5). Comparison with CKD cohorts, predominantly influenced by eGFR-related genetics, uncovered unique kidney failure-specific genetic signatures, highlighting kidney failure as a genetically heterogeneous and multifactorial disease beyond CKD. Conclusions: This study identified subtype-specific genetic loci and demonstrated that multi-PRS models improve kidney failure risk prediction beyond basic available clinical factors.
- 17 June 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Genetic Landscape of Kidney Failure in a Korean Transplant Cohort
Background: Kidney failure represents the final, irreversible stage of chronic kidney disease (CKD), yet its genetic architecture remains incompletely defined compared to CKD. While prior studies largely focused on kidney function traits, the genetic determinants of kidney failure itself and its etiologic subtypes are poorly understood. Therefore, this study aimed to identify genetic loci associated with kidney failure and its subtypes and to evaluate the predictive performance of multiple polygenic risk scores (PRSs) for stratifying kidney failure risk. Methods: We performed a large-scale genome-wide association study (GWAS) using a dataset of 2,355 kidney failure patients across three subtypes defined by primary disease, along with 152,131 controls. PRSs for type 2 diabetes, hypertension, estimated glomerular filtration rate (eGFR), and CKD were calculated, and a multi-PRS model was derived. Results: The GWAS identified multiple kidney failure-associated loci, including HLA-DRB1 for all kidney failure and glomerulonephritis as the primary disease, and COL24A1 for hypertensive kidney failure at genome-wide significance (P-8 ), implicating distinct immune and hypertension-related pathways in kidney failure pathogenesis. PRS analysis revealed that genetically distinct components of type 2 diabetes, hypertension, CKD, and eGFR were significantly linked to kidney failure risk across subtypes (OR=1.1–2.5). A combined multi-PRS model demonstrated superior predictive performance (OR=1.5–2.5). Comparison with CKD cohorts, predominantly influenced by eGFR-related genetics, uncovered unique kidney failure-specific genetic signatures, highlighting kidney failure as a genetically heterogeneous and multifactorial disease beyond CKD. Conclusions: This study identified subtype-specific genetic loci and demonstrated that multi-PRS models improve kidney failure risk prediction beyond basic available clinical factors.
- Open Access
- 19 April 2026
- Published by Elsevier in SSRN Electronic Journal
Unified Multimodal Deep Learning ECG Framework for Laboratory Value Estimation and Abnormality Probability Inference: Multicohort External Validation
Background: We developed and externally validated a 12-lead ECG-based multimodal deep learning framework to estimate multiple laboratory values and derive abnormality probability scores from the same predictive distribution.Methods: In this retrospective study, adult (≥18 years) 10-s 12-lead ECGs at Seoul National University Hospital (SNUH) were linked to the nearest laboratory results within ±24 h to construct ECG–laboratory records. A 1D Swin Transformer predicted 35 laboratory values and modelled uncertainty using a Student-t negative log-likelihood. Abnormality probability scores for 49 labels defined by reference limits were derived from the predictive distribution and evaluated using AUROC. Self-supervised pretraining used lead-wise masked reconstruction on SNUH and public ECG datasets. Fine-tuning integrated the index ECG with age, sex, and up to five prior ECG–laboratory records. Internal validation used patient-wise five-fold cross-validation in SNUH; external validation evaluated the final model in Seoul National University Bundang Hospital (SNUBH), SNUH Healthcare System Gangnam Center (SNUH-HSGC), and MIMIC-IV.Findings: The SNUH cohort included 1,899,753 ECG–laboratory records (696,105 patients; mean age 58·8 [SD 16·3] years; 45·9% male). Median Spearman correlations across values were 0·579, 0·550, 0·386, and 0·471 in internal validation, SNUBH, SNUH-HSGC, and MIMIC-IV, respectively. Haemoglobin (0·765 internally; 0·692–0·776 externally), creatinine (0·706; 0·705–0·719), and NT-proBNP showed strong correlations (0·826; 0·738–0·839). Ablation analyses showed contributions from encoder pretraining and contextual inputs, with the largest gains from memory context. For abnormalities, median AUROC was 0·824 internally and 0·817, 0·745, and 0·755 externally; discrimination remained strong for uraemia (0·914 internally; 0·838–0·909 externally), elevated creatinine (0·927; 0·888–0·938), anaemia (0·885; 0·823–0·875), high haemoglobin (0·879; 0·859–0·891), and elevated NT-proBNP (0·923; 0·900–0·911).Interpretation: This distributional multimodal ECG framework may support triage and test prioritisation when blood sampling is delayed, impractical, or resource-constrained, by estimating multiple laboratory values and deriving abnormality probability scores, with generally retained performance under external validation.
- 19 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessUnified Multimodal Deep Learning ECG Framework for Laboratory Value Estimation and Abnormality Probability Inference: Multicohort External Validation
Background: We developed and externally validated a 12-lead ECG-based multimodal deep learning framework to estimate multiple laboratory values and derive abnormality probability scores from the same predictive distribution.Methods: In this retrospective study, adult (≥18 years) 10-s 12-lead ECGs at Seoul National University Hospital (SNUH) were linked to the nearest laboratory results within ±24 h to construct ECG–laboratory records. A 1D Swin Transformer predicted 35 laboratory values and modelled uncertainty using a Student-t negative log-likelihood. Abnormality probability scores for 49 labels defined by reference limits were derived from the predictive distribution and evaluated using AUROC. Self-supervised pretraining used lead-wise masked reconstruction on SNUH and public ECG datasets. Fine-tuning integrated the index ECG with age, sex, and up to five prior ECG–laboratory records. Internal validation used patient-wise five-fold cross-validation in SNUH; external validation evaluated the final model in Seoul National University Bundang Hospital (SNUBH), SNUH Healthcare System Gangnam Center (SNUH-HSGC), and MIMIC-IV.Findings: The SNUH cohort included 1,899,753 ECG–laboratory records (696,105 patients; mean age 58·8 [SD 16·3] years; 45·9% male). Median Spearman correlations across values were 0·579, 0·550, 0·386, and 0·471 in internal validation, SNUBH, SNUH-HSGC, and MIMIC-IV, respectively. Haemoglobin (0·765 internally; 0·692–0·776 externally), creatinine (0·706; 0·705–0·719), and NT-proBNP showed strong correlations (0·826; 0·738–0·839). Ablation analyses showed contributions from encoder pretraining and contextual inputs, with the largest gains from memory context. For abnormalities, median AUROC was 0·824 internally and 0·817, 0·745, and 0·755 externally; discrimination remained strong for uraemia (0·914 internally; 0·838–0·909 externally), elevated creatinine (0·927; 0·888–0·938), anaemia (0·885; 0·823–0·875), high haemoglobin (0·879; 0·859–0·891), and elevated NT-proBNP (0·923; 0·900–0·911).Interpretation: This distributional multimodal ECG framework may support triage and test prioritisation when blood sampling is delayed, impractical, or resource-constrained, by estimating multiple laboratory values and deriving abnormality probability scores, with generally retained performance under external validation.
- Open Access
- 1 March 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 45 (2) , 274-283
Study protocol for a consortium linking health medical records, biospecimens, and biosignals in Korean patients with acute kidney injury (LINKA cohort)
Background: Acute kidney injury (AKI) may transition into acute kidney disease (AKD) or chronic kidney disease (CKD), leading to subacute and chronic deterioration, respectively. Despite extensive research on AKI, a significant gap exists in understanding the specific biomarkers and development of individualized treatments prior to progression to AKD and CKD.Methods: As a consortium linking health medical records, biospecimens, and biosignals, eight Korean tertiary hospitals participated in the establishment of a retrospective and prospective cohort, each comprising approximately 1,500 patients with AKI receiving continuous kidney replacement therapy (CKRT). Other information included AKI-related information, CKRT prescriptions, and patient outcomes. Follow-up timeframes were set at baseline, 1 week, 3 months, and 1 year after the initiation of CKRT. Human biospecimens will be collected from the prospective cohort. An artificial intelligence model was developed using the retrospective cohort to predict the prognosis of AKD and its subsequent sequelae and to formulate patient-individualized treatments, with validation planned in a prospective cohort. Follow-up studies are scheduled to identify biomarkers related to outcomes using biospecimens. Finally, based on the results and literature review, decision-making on the prevention and management of diseases, as well as the development of treatment guidelines, are being planned.Conclusion: This study will provide scientific evidence on clinical insights and appropriate management targets for AKI and AKD, which will form the basis for relevant treatment guidelines. Additionally, these findings may facilitate a more personalized approach to patient care, enabling clinicians to tailor treatments based on individual biomarker profiles and predictive models.
- 1 March 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 45 (2) , 274-283
Open AccessStudy protocol for a consortium linking health medical records, biospecimens, and biosignals in Korean patients with acute kidney injury (LINKA cohort)
Background: Acute kidney injury (AKI) may transition into acute kidney disease (AKD) or chronic kidney disease (CKD), leading to subacute and chronic deterioration, respectively. Despite extensive research on AKI, a significant gap exists in understanding the specific biomarkers and development of individualized treatments prior to progression to AKD and CKD.Methods: As a consortium linking health medical records, biospecimens, and biosignals, eight Korean tertiary hospitals participated in the establishment of a retrospective and prospective cohort, each comprising approximately 1,500 patients with AKI receiving continuous kidney replacement therapy (CKRT). Other information included AKI-related information, CKRT prescriptions, and patient outcomes. Follow-up timeframes were set at baseline, 1 week, 3 months, and 1 year after the initiation of CKRT. Human biospecimens will be collected from the prospective cohort. An artificial intelligence model was developed using the retrospective cohort to predict the prognosis of AKD and its subsequent sequelae and to formulate patient-individualized treatments, with validation planned in a prospective cohort. Follow-up studies are scheduled to identify biomarkers related to outcomes using biospecimens. Finally, based on the results and literature review, decision-making on the prevention and management of diseases, as well as the development of treatment guidelines, are being planned.Conclusion: This study will provide scientific evidence on clinical insights and appropriate management targets for AKI and AKD, which will form the basis for relevant treatment guidelines. Additionally, these findings may facilitate a more personalized approach to patient care, enabling clinicians to tailor treatments based on individual biomarker profiles and predictive models.
- Open Access
- 31 January 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 44 (1) , 79-90
Comparison between characteristics of immunoglobulin M nephropathy and other glomerular diseases
Background: Immunoglobulin M (IgM) nephropathy (IgMN) is characterized by the IgM deposition in the kidney’s mesangium. We assessed the impact of electron-dense deposits (EDDs) on IgMN and compared it to other kidney diseases. Methods: We enrolled 63 adult patients with IgMN who underwent renal biopsy from May 2003 to June 2017. We compared clinicopathological features of IgMN based on EDD presence; compared characteristics to 91 minimal change disease (MCD), 103 focal segmental glomerulosclerosis (FSGS), and 469 immunoglobulin A nephropathy (IgAN) patients. Renal events were defined as a >50% decrease in estimated glomerular filtration rate (eGFR), eGFR of <15 mL/min/1.73 m2, or end-stage renal disease development. Results: IgMN patients with EDDs had increased mesangial cellularity, matrix accumulation, prominent immunofluorescent staining, and more diffuse podocyte effacement than those without EDD. Clinical characteristics and renal outcomes did not differ significantly based on EDD presence. During 79.5 ± 58.8 months of follow-up, renal events developed in 46.2% and 46.0% of IgMN cases with and without EDD. IgMN (46.0%) and FSGS cases (40.8%) had similar frequencies of renal events and higher frequency than MCD (18.7%) or IgAN cases (26.4%). IgMN cases had more severe manifestations than MCD and IgAN; higher blood pressure, lower proteinuria, and eGFR levels at biopsy than MCD cases; higher blood pressure, proteinuria, frequency of acute kidney injury, and lower eGFR levels. Conclusion: Clinical characteristics of IgMN did not differ based on EDD presence. Therefore, IgMN should be defined based on IF findings. IgMN shared clinical characteristics with FSGS but had more severe than MCD and IgAN.
- 31 January 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 44 (1) , 79-90
Open AccessComparison between characteristics of immunoglobulin M nephropathy and other glomerular diseases
Background: Immunoglobulin M (IgM) nephropathy (IgMN) is characterized by the IgM deposition in the kidney’s mesangium. We assessed the impact of electron-dense deposits (EDDs) on IgMN and compared it to other kidney diseases. Methods: We enrolled 63 adult patients with IgMN who underwent renal biopsy from May 2003 to June 2017. We compared clinicopathological features of IgMN based on EDD presence; compared characteristics to 91 minimal change disease (MCD), 103 focal segmental glomerulosclerosis (FSGS), and 469 immunoglobulin A nephropathy (IgAN) patients. Renal events were defined as a >50% decrease in estimated glomerular filtration rate (eGFR), eGFR of <15 mL/min/1.73 m2, or end-stage renal disease development. Results: IgMN patients with EDDs had increased mesangial cellularity, matrix accumulation, prominent immunofluorescent staining, and more diffuse podocyte effacement than those without EDD. Clinical characteristics and renal outcomes did not differ significantly based on EDD presence. During 79.5 ± 58.8 months of follow-up, renal events developed in 46.2% and 46.0% of IgMN cases with and without EDD. IgMN (46.0%) and FSGS cases (40.8%) had similar frequencies of renal events and higher frequency than MCD (18.7%) or IgAN cases (26.4%). IgMN cases had more severe manifestations than MCD and IgAN; higher blood pressure, lower proteinuria, and eGFR levels at biopsy than MCD cases; higher blood pressure, proteinuria, frequency of acute kidney injury, and lower eGFR levels. Conclusion: Clinical characteristics of IgMN did not differ based on EDD presence. Therefore, IgMN should be defined based on IF findings. IgMN shared clinical characteristics with FSGS but had more severe than MCD and IgAN.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (36) , e242
Analysis of Self-Sufficiency and Factors Affecting Migration Between Medical Service Regions in Korea Among CKD Patients
You EM, et al. J Korean Med Sci. 2025 Aug;40:e242. https://doi.org/10.3346/jkms.2025.40.e242
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (36) , e242
Open AccessAnalysis of Self-Sufficiency and Factors Affecting Migration Between Medical Service Regions in Korea Among CKD Patients
You EM, et al. J Korean Med Sci. 2025 Aug;40:e242. https://doi.org/10.3346/jkms.2025.40.e242
- Open Access
- 8 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5121
Characterizing Glomerular Barrier Dysfunction with Patient-Derived Serum in Glomerulus-on-a-Chip Models: Unveiling New Insights into Glomerulonephritis
Glomerulonephritis (GN) is characterized by podocyte injury or glomerular filtration dysfunction, which results in proteinuria and eventual loss of kidney function. Progress in studying the mechanism of GN, and developing an effective therapy, has been limited by the absence of suitable in vitro models that can closely recapitulate human physiological responses. We developed a microfluidic glomerulus-on-a-chip device that can recapitulate the physiological environment to construct a functional filtration barrier, with which we investigated biological changes in podocytes and dynamic alterations in the permeability of the glomerular filtration barrier (GFB) on a chip. We also evaluated the potential of GN-mimicking devices as a model for predicting responses to human GN. Glomerular endothelial cells and podocytes successfully formed intact monolayers on opposite sides of the membrane in our chip device. Permselectivity analysis confirmed that the chip was constituted by a functional GFB that could accurately perform differential clearance of albumin and dextran. Reduction in cell viability resulting from damage was observed in all serum-induced GN models. The expression of podocyte-specific marker WT1 was also decreased. Albumin permeability was increased in most models of serum-induced IgA nephropathy (IgAN) and membranous nephropathy (MN). However, sera from patients with minimal change disease (MCD) or lupus nephritis (LN) did not induce a loss of permeability. This glomerulus-on-a-chip system may provide a platform of glomerular cell culture for in vitro GFB in formation of a functional three-dimensional glomerular structure. Establishing a disease model of GN on a chip could accelerate our understanding of pathophysiological mechanisms of glomerulopathy.
- 8 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5121
Open AccessCharacterizing Glomerular Barrier Dysfunction with Patient-Derived Serum in Glomerulus-on-a-Chip Models: Unveiling New Insights into Glomerulonephritis
Glomerulonephritis (GN) is characterized by podocyte injury or glomerular filtration dysfunction, which results in proteinuria and eventual loss of kidney function. Progress in studying the mechanism of GN, and developing an effective therapy, has been limited by the absence of suitable in vitro models that can closely recapitulate human physiological responses. We developed a microfluidic glomerulus-on-a-chip device that can recapitulate the physiological environment to construct a functional filtration barrier, with which we investigated biological changes in podocytes and dynamic alterations in the permeability of the glomerular filtration barrier (GFB) on a chip. We also evaluated the potential of GN-mimicking devices as a model for predicting responses to human GN. Glomerular endothelial cells and podocytes successfully formed intact monolayers on opposite sides of the membrane in our chip device. Permselectivity analysis confirmed that the chip was constituted by a functional GFB that could accurately perform differential clearance of albumin and dextran. Reduction in cell viability resulting from damage was observed in all serum-induced GN models. The expression of podocyte-specific marker WT1 was also decreased. Albumin permeability was increased in most models of serum-induced IgA nephropathy (IgAN) and membranous nephropathy (MN). However, sera from patients with minimal change disease (MCD) or lupus nephritis (LN) did not induce a loss of permeability. This glomerulus-on-a-chip system may provide a platform of glomerular cell culture for in vitro GFB in formation of a functional three-dimensional glomerular structure. Establishing a disease model of GN on a chip could accelerate our understanding of pathophysiological mechanisms of glomerulopathy.
- Open Access
- 29 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (21) , 15726
Efficacy of Mesenchymal-Stromal-Cell-Derived Extracellular Vesicles in Ameliorating Cisplatin Nephrotoxicity, as Modeled Using Three-Dimensional, Gravity-Driven, Two-Layer Tubule-on-a-Chip (3D-MOTIVE Chip)
Mesenchymal stromal cell (MSC)-derived extracellular vesicles (EVs) are known to have a therapeutic effect on nephrotoxicity. As animal models require significant time and resources to evaluate drug effects, there is a need for a new experimental technique that can accurately predict drug effects in humans. We evaluated the therapeutic effect of MSC-derived EVs in cisplatin nephrotoxicity using a three-dimensional, gravity-driven, two-layer tubule-on-a-chip (3D-MOTIVE chip). In the 3D-MOTIVE chip, 10 μM cisplatin decreased the number of attached cells compared to the vehicle. Conversely, annexin V and reactive oxygen species (ROS) were increased. Cell viability was increased 2.8-fold and 2.5-fold after treatment with EVs at 4 and 8 µg/mL, respectively, compared to the cisplatin-induced nephrotoxicity group. Cell attachment was increased 2.25-fold by treatment with 4 µg/mL EVs and 2.02-fold by 8 µg/mL EVs. Annexin V and ROS levels were decreased compared to those in the cisplatin-induced nephrotoxicity group. There were no significant differences in annexin V and ROS levels according to EV concentration. In sum, we created a cisplatin-induced nephrotoxicity model on a 3D-MOTIVE chip and found that MSC-derived EVs could restore cell viability. Thus, MSC-derived EVs may have the potential to ameliorate cisplatin-induced nephrotoxicity.
- 29 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (21) , 15726
Open AccessEfficacy of Mesenchymal-Stromal-Cell-Derived Extracellular Vesicles in Ameliorating Cisplatin Nephrotoxicity, as Modeled Using Three-Dimensional, Gravity-Driven, Two-Layer Tubule-on-a-Chip (3D-MOTIVE Chip)
Mesenchymal stromal cell (MSC)-derived extracellular vesicles (EVs) are known to have a therapeutic effect on nephrotoxicity. As animal models require significant time and resources to evaluate drug effects, there is a need for a new experimental technique that can accurately predict drug effects in humans. We evaluated the therapeutic effect of MSC-derived EVs in cisplatin nephrotoxicity using a three-dimensional, gravity-driven, two-layer tubule-on-a-chip (3D-MOTIVE chip). In the 3D-MOTIVE chip, 10 μM cisplatin decreased the number of attached cells compared to the vehicle. Conversely, annexin V and reactive oxygen species (ROS) were increased. Cell viability was increased 2.8-fold and 2.5-fold after treatment with EVs at 4 and 8 µg/mL, respectively, compared to the cisplatin-induced nephrotoxicity group. Cell attachment was increased 2.25-fold by treatment with 4 µg/mL EVs and 2.02-fold by 8 µg/mL EVs. Annexin V and ROS levels were decreased compared to those in the cisplatin-induced nephrotoxicity group. There were no significant differences in annexin V and ROS levels according to EV concentration. In sum, we created a cisplatin-induced nephrotoxicity model on a 3D-MOTIVE chip and found that MSC-derived EVs could restore cell viability. Thus, MSC-derived EVs may have the potential to ameliorate cisplatin-induced nephrotoxicity.
- Open Access
- 30 September 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 42 (5) , 606-616
Electronic alert outpatient protocol improves the quality of care for the risk of postcontrast acute kidney injury following computed tomography
Background: Prevention and diagnosis of postcontrast acute kidney injury (AKI) after contrast-enhanced computed tomography is burdensome in outpatient department. We investigated whether an electronic alert system could improve prevention and diagnosis of postcontrast AKI. Methods: In March 2018, we launched an electronic alert system that automatically identifies patients with a baseline estimated glomerular filtration rate of <45 mL/min/1.73 m2, provides a prescription of fluid regimen, and recommends a follow-up for serum creatinine measurement. Participants prescribed contrast-enhanced computed tomography at outpatient department before and after the launch of the system were categorized as historical and alert group, respectively. Propensity for the surveillance of postcontrast AKI was compared using logistic regression. Risks of AKI, admission, mortality, and renal replacement therapy were analyzed. Results: The historical and alert groups included 289 and 309 participants, respectively. The alert group was more likely to be men and take diuretics. The most frequent volume of prophylactic fluid in historical and alert group was 1,000 and 750 mL, respectively. Follow-up for AKI was more common in the alert group (adjusted odds ratio, 6.00; p < 0.001). Among them, incidence of postcontrast AKI was not statistically different. The two groups did not differ in risks of admission, mortality, or renal replacement therapy. Conclusion: The electronic alert system could assist in the detection of high-risk patients, prevention with reduced fluid volume, and proper diagnosis of postcontrast AKI, while limiting the prescribing clinicians’ burden. Whether the system can improve long-term outcomes remains unclear.
- 30 September 2023
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 42 (5) , 606-616
Open AccessElectronic alert outpatient protocol improves the quality of care for the risk of postcontrast acute kidney injury following computed tomography
Background: Prevention and diagnosis of postcontrast acute kidney injury (AKI) after contrast-enhanced computed tomography is burdensome in outpatient department. We investigated whether an electronic alert system could improve prevention and diagnosis of postcontrast AKI. Methods: In March 2018, we launched an electronic alert system that automatically identifies patients with a baseline estimated glomerular filtration rate of <45 mL/min/1.73 m2, provides a prescription of fluid regimen, and recommends a follow-up for serum creatinine measurement. Participants prescribed contrast-enhanced computed tomography at outpatient department before and after the launch of the system were categorized as historical and alert group, respectively. Propensity for the surveillance of postcontrast AKI was compared using logistic regression. Risks of AKI, admission, mortality, and renal replacement therapy were analyzed. Results: The historical and alert groups included 289 and 309 participants, respectively. The alert group was more likely to be men and take diuretics. The most frequent volume of prophylactic fluid in historical and alert group was 1,000 and 750 mL, respectively. Follow-up for AKI was more common in the alert group (adjusted odds ratio, 6.00; p < 0.001). Among them, incidence of postcontrast AKI was not statistically different. The two groups did not differ in risks of admission, mortality, or renal replacement therapy. Conclusion: The electronic alert system could assist in the detection of high-risk patients, prevention with reduced fluid volume, and proper diagnosis of postcontrast AKI, while limiting the prescribing clinicians’ burden. Whether the system can improve long-term outcomes remains unclear.
- 19 August 2023
- Published by Elsevier in Journal of Immunological Methods
- Vol. 521, 113537
Application of microphysiologic system to assess neutrophil extracellular trap in xenotransplantation
- 19 August 2023
- Published by Elsevier in Journal of Immunological Methods
- Vol. 521, 113537
Application of microphysiologic system to assess neutrophil extracellular trap in xenotransplantation